{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:41:52Z","timestamp":1793914912758,"version":"4.8.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with type 2 inflammation. While biologics are a promising treatment for patients with uncontrolled CRSwNP, real-world evidence is needed to optimize their use. The InternatioNal seVerE CRSwNP (INVENT) registry aims to consolidate data on biologic use in CRSwNP from local and national registries. This study describes the identification of mandatory and optional variables for inclusion in the INVENT registry using a modified Delphi process.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A narrative literature review was performed to identify variables reported in real-world studies of biologic treatment for CRSwNP. A modified Delphi study was conducted between December 2024 and March 2025 involving 23 experts from Europe and Australia. Experts rated the clinical relevance of candidate variables in two online survey rounds using 9-point Likert scales. A positive response was defined as \u226570% of respondents rating a variable 7\u20139 and \u226415% rating it 1\u20133. Final agreement on mandatory and optional variables was reached through panel discussion. A validation survey was then conducted across registry centers to assess the feasibility of collecting the selected variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The Delphi process resulted in consensus on a core set of mandatory and optional variables across nine domains: demographics, medical history, previous and current biologic therapy, biomarkers, comorbidities, asthma, CRSwNP-specific outcomes, and follow-up variables. The validation survey confirmed that most mandatory variables were available or obtainable across participating centers, supporting the feasibility of data collection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This international Delphi study identified a consensus-based set of clinically-relevant and feasible variables for inclusion in the INVENT registry. The selected variables reflect current best practices in the management of CRSwNP and will enable robust comparisons of biologic effectiveness in real-world settings. The INVENT registry is well-positioned to inform treatment decisions, optimize use of biologics, and support a personalized approach to CRSwNP care.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1680703","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:26:51Z","timestamp":1760333211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-life evaluation of the effectiveness of biologics for chronic rhinosinusitis with nasal polyps in Europe: a Delphi study to define key variables for the INVENT registry"],"prefix":"10.3389","volume":"6","author":[{"given":"Vibeke","family":"Backer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"De Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Mortuaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Prokopakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Dr\u00f8hse Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Chaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"von Buchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bequignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Brozek-Madry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannis","family":"Constantinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske J.","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Grande Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietze","family":"Reitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Toppila-Salmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Soyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/all.15982","article-title":"EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care","volume":"79","author":"Hellings","year":"2024","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4193\/Rhin23.415","article-title":"EPOS2020\/EUFOREA Expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1372919","DOI":"10.3389\/falgy.2024.1372919","article-title":"Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA","volume":"5","author":"Teeling","year":"2024","journal-title":"Front Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","article-title":"Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis","volume":"36","author":"Chen","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European Position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4193\/Rhin22.344","article-title":"The EUFOREA pocket guide for chronic rhinosinusitis","volume":"61","author":"Hellings","year":"2023","journal-title":"Rhinology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4193\/Rhin24.510","article-title":"Pocket guide: biologics in upper and lower airways in adults","volume":"63","author":"Fokkens","year":"2025","journal-title":"Rhinology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/jpm12081251","article-title":"Sinonasal biomarkers defining type 2-high and type 2-low inflammation in chronic rhinosinusitis with nasal polyps","volume":"12","author":"De Corso","year":"2022","journal-title":"J Pers Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1192284","DOI":"10.3389\/fimmu.2023.1192284","article-title":"Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach","volume":"14","author":"Quirce","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The global allergy and asthma European network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/jaa.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e022644","DOI":"10.1136\/bmjopen-2018-022644","article-title":"Chronic rhinosinusitis: a qualitative study of patient views and experiences of current management in primary and secondary care","volume":"9","author":"Vennik","year":"2019","journal-title":"BMJ Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"761388","DOI":"10.3389\/falgy.2021.761388","article-title":"Patients unmet needs in chronic rhinosinusitis with nasal polyps care: a patient advisory board statement of EUFOREA","volume":"2","author":"Claeys","year":"2021","journal-title":"Front Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4193\/Rhin19.158","article-title":"The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1236977","DOI":"10.3389\/falgy.2023.1236977","article-title":"EUFOREA Summit in Brussels 2023: inspiring the future of allergy & respiratory care","volume":"4","author":"Hellings","year":"2023","journal-title":"Front Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin24.090","article-title":"Outcome measures for chronic rhinosinusitis with nasal polyps","volume":"62","author":"Sedaghat","year":"2024","journal-title":"Rhinology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13223-023-00855-7","article-title":"Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study","volume":"19","author":"Silver","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/iid3.46","article-title":"A retrospective, cross-sectional study reveals that women with CRSwNP have more severe disease than men","volume":"3","author":"Stevens","year":"2015","journal-title":"Immun Inflamm Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.4193\/Rhin21.253","article-title":"Multi-institutional minimal clinically important difference of the 22-item sinonasal outcome test in medically managed chronic rhinosinusitis","volume":"59","author":"Phillips","year":"2021","journal-title":"Rhinology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/lary.29888","article-title":"Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis","volume":"132","author":"Han","year":"2022","journal-title":"Laryngoscope"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.3390\/nu16172982","article-title":"Impact of overweight on response to dupilumab treatment in chronic rhinosinusitis with nasal polyps","volume":"16","author":"Habenbacher","year":"2024","journal-title":"Nutrients"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/alr.23049","article-title":"Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis","volume":"12","author":"Giombi","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"P3448","DOI":"10.1183\/13993003\/erj.42.Suppl_57.P3448","article-title":"Chronic rhinosinusitis with and without nasal polyps and rhinitis in adult asthma. Frequency distribution and relationship with asthma control and severity (the IRIS-ASMA study)","volume":"42","author":"Castillo","year":"2014","journal-title":"Eur Respir J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.anai.2022.01.025","article-title":"Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma","volume":"128","author":"Geng","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1680703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:26:53Z","timestamp":1760333213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1680703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":34,"alternative-id":["10.3389\/falgy.2025.1680703"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1680703","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1680703"}}